The tainted heparin story: An update

Thrombosis and Haemostasis

Volumn 102, Issue 5, 2009, Pages 907-911

  Guerrini, Marco ^a   Shriver, Zachary ^b   Bisio, Antonella ^a   Naggi, Annamaria ^a   Casu, Benito ^a   Sasisekharan, Ram ^b   Torri, Giangiacomo ^a  

^a Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Glycosaminoglycans; Heparins; Magnetic resonance

Indexed keywords

CHONDROITIN SULFATE; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN; ION EXCHANGE RESIN; POLYSACCHARIDE; SULFATE;

ANALYTIC METHOD; ANAPHYLAXIS; CONFERENCE PAPER; DRUG CONTAMINATION; DRUG PURITY; DRUG QUALITY; DRUG SAFETY; DRUG SYNTHESIS; HETERONUCLEAR MULTIPLE BOND CORRELATION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SCREENING TEST; SULFATION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; ANTICOAGULANTS; CHILD; CHONDROITIN SULFATES; COMPLEMENT ACTIVATION; DISEASE OUTBREAKS; DRUG CONTAMINATION; DRUG HYPERSENSITIVITY; HEPARIN; HUMANS; KALLIKREINS; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME; SULFATES; SWINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70449581256     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-02-0079     Document Type: Conference Paper

References (11)

1. Contaminant detected in heparin material of specified origin in the USA and in Germany; serious adverse events reported; recall measures initiated. World Health Organization Alert No.118 (7 March 2008). 〈http://www.who.int/ medicines/publications/drugalerts/Alert-118-Heparin.pdf〉
2. Notice of Recall from Rotexmedica to Bfarm (German Regulatory Authorities). Rotexmedica/Bfarm Notice (7 March 2008).http://www.akdae.de/20/40/ Archiv/2008/20080310.pdf
3. Communication. Information on heparin sodium injection. US Food and Drug Administration. http://www.fda.gov/cder/drug/infopage/heparin/default.htm
4. Guerrini M, Beccati D, Shriver Z, et al. Oversulfated chondroitinsulfate is a contaminant in heparin associated with adverse clinical events. Nature Biotechnol. 2008; 26: 669-675. (Pubitemid 351824692)
5. Kishimoto TK, Viswanathan K, Ganguly T. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl. J Med 2008; 358: 2457-2467. (Pubitemid 351793019)
6. Blossom DB, Kallen AJ, Pate PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359: 2674-2684.
7. Casu B (2005) Structure and active domains of heparin. In Chemistry and Biology of Heparin and Heparan Sulfate (Garg, H. G., Linhardt R J, and Hales CA, eds) pp. 1-28, Elsevier, Ltd., Oxford, UK.
8. Pharmacopeial Forum. Proposed heparin sodium monograph. [Mar.-Apr. 2009] Vol.35 (2) http://www.usp.org/hottopics/heparin.html.
9. 13C-NMR spectroscopy for characterization of heparin preparations. Semin. Thromb. Hemostas 2001; 27: 473-482.
10. 1H NMR chemical shift of the methyl signal of oversulphated chondroitin sulphate, a contaminant in heparin. J of Pharm and Biomed Anal 2009; 49: 816-819.
11. Guerrini M, Naggi A, Guglieri S, et al. Complex glycosaminoglycans: profiling substitution patterns by two dimensional nmr spectroscopy. Anal Biochem 2005; 337: 35-47. (Pubitemid 40092776)